Table 1.
Study population and case demographic and clinical characteristics
| Characteristics | Study population (N = 634) | Retinopathy cases (n = 11) |
|---|---|---|
| Age at HCQ initiation, mean (s.d.), years | 53.7 (15.5) | 58.1 (11.5) |
| Sex, female, n (%) | 502 (79) | 10 (91) |
| Race/ethnicity, n (%) | ||
| White | 580 (91) | 10 (91) |
| Asian | 9 (1) | – |
| Other/mixed | 7 (1) | 1 (9) |
| Black | 10 (2) | – |
| American Indian | 3 (0.5) | – |
| Hispanic | 24 (4) | – |
| Indication for HCQ, n (%) | ||
| RAa | 363 (57) | 10 (91) |
| SLE | 120 (19) | – |
| CTDb | 61 (10) | – |
| Dermatologic | 35 (6) | – |
| Sjogren’s | 33 (5) | 1 (9) |
| Otherc | 20 (3) | – |
| BMI, kg/m2, mean (s.d.) | 29.8 (7.2) | 28.6 (5.0) |
| Presence of CKD, n (%) | 66 (10) | 3 (27) |
| HCQ dose, mg/day, mean (s.d.) | 356.9 (91.3) | 400 (0) |
| Range | 100–800 | 400–400 |
| HCQ dose, mg/kg/dayd, mean (s.d.) | 4.5 (1.4) | 5.7 (1.1) |
| Range | 1.3–8.9 | 3.8–6.7 |
| Cumulative HCQ dose, g, mean (s.d.) | 472 (131) | 540 (38) |
| Range | 24–725 | 463–585 |
| Length of follow up, years, mean (s.d.), median (Q1–Q3) (IQR) | 7.6 (2.7) | 8.1 (2.0) |
| 7.1 (2.5–7.8) (5.3) | 8.3 (3.3–9.2) (5.9) |
a
Seronegative, seropositive, RA/SLE overlap.
b
MCTD, UCTD, DM, APS, scleroderma.
c
Inflammatory OA, CPPD, palindromic rheumatism, Blau syndrome.
d
Actual body weight (in kg).